Azevan is a company headquartered in the United States.
Azevan Pharmaceuticals is developing vasopressin V1a receptor antagonists as targeted treatments for pathological aggression and neurological injury in CNS disorders and traumatic brain injury.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.